Drugs / BELUDAVIMAB
BELUDAVIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04746183 | Jul 2020 → Mar 2027 expected | COVID-19 | University of Liverpool | Recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-04-08 | Vir Biotechnology, Inc. | Results Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells vir.bio ↗
The research highlights the distinct mechanism of action of non-receptor-binding motif (RBM)-targeting antibodies, such as VIR-7831 and VIR-7832, the Company’s investigational SARS-CoV-2 mAbs that target a conserved non-RBM site within the receptor binding domain (RBD). |
| 2020-11-06 | Vir Biotechnology, Inc. | Results Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K vir.bio ↗
When tested across four clinical-stage antibodies – S309 (the precursor of VIR-7831), LY-CoV555, REGN10933 and REGN10987 – S309, which targets a non-RBM epitope, LY-CoV555 and REGN10933 were capable of neutralizing the N439K variant. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-04-08 | Vir Biotechnology, Inc. | Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells vir.bio ↗ |
| 2021-01-12 | GlaxoSmithKline | Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19 gsk.com ↗ |
| 2021-01-12 | Vir Biotechnology, Inc. | Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 vir.bio ↗ |
| 2020-11-06 | Vir Biotechnology, Inc. | Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K vir.bio ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BELUDAVIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802220 ↗ |
| Known as | GSK-4182137 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802220 ↗ |
| Known as | VIR-7832 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04746183 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4802220 ↗ |
| Route | Intravenous | “VIR-7832 will be administered by intravenous (IV) infusion over 1 hour.” NCT04746183 ↗ |